Optimus Pharma gets DCGI gesture to lead Phase-3 preliminary of COVID-19 antiviral drug

Overview

• Post By :


• Source: AP


• Date: 19 May,2021

The orally administered drug is being tested for treating mild and moderate infection

Optimus Pharma has obtained the approval of the Drug Controller General of India (DCGI) to conduct Phase III clinical trials of orally administered Molnupiravir capsules on patients with mild and moderate Covid-19 infection.

In accordance with the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate Covid-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care.